Phase II/III CRO Benchmarking (17th Ed.)

Report Overview

Our series of CRO Benchmarking reports has been designed with two goals in mind. The first goal is to help biopharmaceutical companies make more informed CRO selection decisions. With so many providers vying for clinical trial work, it can be challenging to find the right fit for a particular sponsor organization or trial. And without prior experience with a CRO, it is difficult to judge how the CRO will perform.

The second goal of this report is to help CROs optimize operational and marketing strategies. Learning your customers’ assessments of your strengths and weaknesses can be invaluable for both the development and marketing of a successful offering. With this report, you’ll understand in which areas your company’s performance shines and in which areas you may need to close the gap relative to competitors. These insights, coupled with findings about which attributes sponsors find important in provider selection, can then be used to design messaging and marketing materials that effectively promote your company’s strengths and differentiators.

For this study, 216 experienced Phase II/III outsourcers shared their insights regarding 806 recent service provider encounters. We analyze a variety of factors around CRO selection and share performance data for 31 CROs on 22 attributes across several categories (Delivery Factors, Staff Characteristics, Services, and Project Delivery across geographies). Sponsors and service providers can use this information to make the best decisions possible for their clinical development programs and service offerings.

What you will learn:

Sponsors:

• Gain insight into CRO customer loyalty based on overall customer satisfaction, willingness to recommend, and likelihood to use again
• Learn which service providers your company could utilize for your clinical development programs by identifying how each CRO has performed for your peers across a variety of metrics
• Discover which attributes motivate outsourcing selection for Phase II/III services
• Understand sponsor satisfaction with the value they received in recent Phase II/III engagements with each provider

Service Providers:

• Understand the selection drivers most important to sponsors when choosing Phase II/III service providers
• Learn from recent customers how your performance compared to their expectations, across 22 attributes
• Hear directly from respondents the reason(s) for their satisfaction ratings for your company’s performance
• Inform your marketing messaging by understanding the areas in which respondents say you excel compared to your competitors
• Understand where your company and your competitors fall on brand metrics such as awareness, familiarity, and perceived leadership

Major Sections:

• Service Provider Selection Process
• Service Provider Perceptions and Interactions
• Service Provider Performance and Loyalty
• Service Provider Cost and Value
• Company Service Quality Profiles
• Appendix
• Service Provider Drill-downs
• Demographics

Included Providers:

• Advanced Clinical
• Allucent
• Altasciences
• Caidya
• ClinChoice
• CTI Clinical Trial & Consulting
• DCRI-Duke
• Eurofins
• Fortrea
• Frontage
• George Clinical
• ICON
• Innovaderm
• IQVIA
• Lambda
• Medpace
• Novotech
• Novum
• Ora
• Parexel
• PPD (part of Thermo Fisher)
• Precision for Medicine
• Premier Research
• ProPharma Group
• ProSciento
• PSI
• QPS
• Rho
• SGS Health Science
• Syneos Health
• UBC
• Veristat
• Worldwide Clinical Trials

Companies listed in bold print have been reviewed by 10 or more respondents. These providers have detailed company service quality profiles and are included in an in-depth performance analysis.